中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
18期
37-38
,共2页
肺癌%中晚期%放化疗
肺癌%中晚期%放化療
폐암%중만기%방화료
Lung cancer%Middle and late stage%Radiotherapy and chemotherapy
目的 分析放化疗在肺癌中晚期患者中的应用效果.方法 选取我院收治的肺癌中晚期患者40名,随机分成同步放化疗组和贯序放化疗组.同步组采用三维适形常规分割放疗治疗的同时进行NP方案化疗,贯序组先行三维适形常规分割放疗,2周后再行NP方案化疗.对治疗效果分别评定,并随诊至2015年3月,比较两组患者的生存率.结果 两组患者治疗1个月后,同步放化疗组总有效率为80%,贯序放化疗组总有效率为40% ;随诊至2015年3月,贯序放化疗组的生存率为45%,同步放化疗组的生存率为60%.两组治疗效果差异明显.结论 同步组的治疗效果、存活率明显好于贯序组.同步放化疗对肺癌中晚期患者有确切的疗效.
目的 分析放化療在肺癌中晚期患者中的應用效果.方法 選取我院收治的肺癌中晚期患者40名,隨機分成同步放化療組和貫序放化療組.同步組採用三維適形常規分割放療治療的同時進行NP方案化療,貫序組先行三維適形常規分割放療,2週後再行NP方案化療.對治療效果分彆評定,併隨診至2015年3月,比較兩組患者的生存率.結果 兩組患者治療1箇月後,同步放化療組總有效率為80%,貫序放化療組總有效率為40% ;隨診至2015年3月,貫序放化療組的生存率為45%,同步放化療組的生存率為60%.兩組治療效果差異明顯.結論 同步組的治療效果、存活率明顯好于貫序組.同步放化療對肺癌中晚期患者有確切的療效.
목적 분석방화료재폐암중만기환자중적응용효과.방법 선취아원수치적폐암중만기환자40명,수궤분성동보방화료조화관서방화료조.동보조채용삼유괄형상규분할방료치료적동시진행NP방안화료,관서조선행삼유괄형상규분할방료,2주후재행NP방안화료.대치료효과분별평정,병수진지2015년3월,비교량조환자적생존솔.결과 량조환자치료1개월후,동보방화료조총유효솔위80%,관서방화료조총유효솔위40% ;수진지2015년3월,관서방화료조적생존솔위45%,동보방화료조적생존솔위60%.량조치료효과차이명현.결론 동보조적치료효과、존활솔명현호우관서조.동보방화료대폐암중만기환자유학절적료효.
Objective To analyze the effect of chemotherapy and chemotherapy in the patients with advanced lung cancer.Methods 40 patients with lung cancer in our hospital were randomly divided into the group of concurrent chemotherapy and sequential chemotherapy. The synchronous group was treated with three-dimensional conformal radiotherapy and NP regimen, and the coherent group was three-dimensional conformal radiotherapy. The NP regimen was performed after 2 weeks. The effect of the treatment was assessed separately, and the survival rate of the two groups was compared with that of March,2015.Results After treatment a month, concurrent chemoradiotherapy group, the total effective rate of 80%, Sequential chemotherapy group, the total effective rate of 40%; follow-up to March 2015, put the survival Sequential chemotherapy group was 45 % survival rate of synchronous radiotherapy and chemotherapy group was 60%. The effect of treatment, significant differences.Conclusion The therapeutic effect and survival rate of the synchronous group were significantly better than the sequence group. Concurrent chemotherapy for the advanced lung cancer patients with the exact effect.
